---
title: "Facing doubts about raw material components again, GIANT BIOGENE responded: Multiple batch test results show collagen is greater than 0.1%"
description: "GIANT BIOGENE's brand KefuMei issued a statement in response to social media influencers questioning the collagen content in its restructuring products, stating that multiple batches of test results s"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/241722786.md"
published_at: "2025-05-24T23:41:11.000Z"
---

# Facing doubts about raw material components again, GIANT BIOGENE responded: Multiple batch test results show collagen is greater than 0.1%

> GIANT BIOGENE's brand KefuMei issued a statement in response to social media influencers questioning the collagen content in its restructuring products, stating that multiple batches of test results show collagen content greater than 0.1%. The test reports indicate that the collagen content of the samples was 0.27%, 0.27%, and 0.28%, respectively. KefuMei also stated that it has commissioned an authoritative third-party organization for further testing and will promptly announce the results

On May 24th, a social media influencer with 430,000 followers posted a video and text post titled "GIANT BIOGENE suspected of fraud: Reconstructed collagen cannot be detected!" On the evening of May 24th, the brand KefuMei under GIANT BIOGENE released a "Stern Statement - Notice to Consumers" on its official social media account. In the statement, KefuMei responded to the core issue: "At the first moment the incident occurred, we conducted tests on the relevant products according to the 'Pharmacopoeia of the People's Republic of China' and other relevant industry standards, and multiple batches of test results showed that the collagen content was greater than 0.1%." Additionally, the account published a "Testing Report of Xi'an GIANT BIOGENE Technology Co., Ltd." which showed that on May 24th, five samples were taken to test for collagen content. The test results were 0.27%, 0.27%, and 0.28%, respectively. Furthermore, the statement mentioned that multiple authoritative third-party testing institutions have been commissioned to conduct further tests on the relevant products using various testing methods, and the results will be announced as soon as possible. Regarding the influencer's testing method, KefuMei responded: "It is not included in the relevant industry standards and has not undergone rigorous methodological validation. At the same time, the influencer has not requested the company for the raw materials of the reconstructed collagen."

### Related Stocks

- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| TABLE-Asian physical rubber prices - February 19 | Feb 19 (Reuters) -Grade PricesThai RSS3 (March) 74.82 baht/kgThai STR20 (March) 66.69 baht/kgThai 60-percent latex (bulk | [Link](https://longbridge.com/en/news/276312097.md) |
| Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection | Mikrobiomik has received approval in Spain for its oral therapy EUTEGRA (MBK-01) to treat Clostridioides difficile infec | [Link](https://longbridge.com/en/news/276345316.md) |
| 09:01 ETPACSUN AND LAFC CELEBRATE HISTORIC OPENING DAY AT THE COLISEUM WITH FIRST 2026 CAPSULE COLLECTION | Pacsun and LAFC celebrate the historic opening day of the 2026 MLS season at the Los Angeles Memorial Coliseum on Februa | [Link](https://longbridge.com/en/news/276342177.md) |
| Synthetik Selected to Support Amentum-Led Team Hypersonics (UK) Industry Mission Partner | Synthetik Applied Technologies UK has been selected to support Amentum as the TeamHx UK Industry Mission Partner, focusi | [Link](https://longbridge.com/en/news/276333245.md) |
| Germany's DB Cargo plans 6,000 job cuts in bid to return to profit | Germany's DB Cargo plans to cut 6,000 jobs, nearly half of its workforce, by 2030 as part of a restructuring effort to r | [Link](https://longbridge.com/en/news/276321523.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
